LeMaitre Vascular Will Announce Fourth Quarter 2020 Earnings Results on February 25, 2021
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will release its fourth quarter 2020 financial results on February 25, 2021, post-market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will release its fourth quarter 2020 financial results on February 25, 2021, post-market. A conference call is scheduled for the same day at 5:00 PM ET to discuss results and company outlook. Investors can dial in or access the call via a webcast at www.lemaitre.com/investor. LeMaitre is known for its devices addressing peripheral vascular disease, a condition impacting over 200 million individuals globally, and offers a diversified product portfolio for vascular surgeons.
Details
News Market Reaction – LMAT
The recorded move for LMAT in the trading session of this news was +2.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2020 financial results on Thursday, February 25, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 8429679. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company’s diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.